Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4213663 · 1 trial · 1 indication
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY4213663 (Part A) | EXPERIMENTAL | Single-ascending dose (SAD) of LY4213663 administered subcutaneously (SC) and intravenously (IV) in healthy participants |
| Placebo (Part A) | PLACEBO_COMPARATOR | SAD placebo administered SC and IV |
| LY4213663 (Part B) | EXPERIMENTAL | Multiple-ascending doses (MAD) of LY4213663 administered SC and IV in healthy participants |
| Placebo (Part B) | PLACEBO_COMPARATOR | MAD placebo administered SC and IV |
| LY4213663 (Parts C and D) | EXPERIMENTAL | Multiple doses of LY4213663 administered SC and IV in participants with RA |
| Name | Type | Description |
|---|---|---|
| LY4213663 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Have a body mass index (BMI) of 18.0 to 32.0 kilogram per square meter (kg/m²), inclusive Part C and D Only: * Have a body weight at least 50 kilograms and BMI within the range 18.0 to 40.0 kg/m² (inclusive) at screening * Have a diagnosis of adult-onset RA for at least 3 mo...
Top 20 of 28 competitors
LY4213663 is an investigational small molecule being developed for the treatment of Rheumatoid Arthritis (RA). It is currently in Phase 1 clinical development, meaning it has not yet been approved and is still being studied for safety and efficacy in clinical trials.
LY4213663 is a small molecule, but its specific molecular target has not been disclosed. It is being studied in the immunology therapeutic area for Rheumatoid Arthritis, suggesting it may modulate immune pathways relevant to the disease, but the exact mechanism of action is not publicly available.
LY4213663 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the stock exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate the drug's safety and effectiveness in participants with Rheumatoid Arthritis.
LY4213663 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to study the drug in healthy volunteers and individuals with Rheumatoid Arthritis.
LY4213663 is being studied in one active clinical trial with the identifier NCT07258849. This Phase 1 study is recruiting 141 participants in the United States and Germany, and it includes healthy volunteers as well as participants with Rheumatoid Arthritis. The trial is placebo-controlled and randomized.
No alternative names for LY4213663 have been disclosed. It is identified solely by its code name LY4213663 in clinical trial registries and by its developer, Eli Lilly and Company. No other drug names or aliases are associated with this investigational compound.